At the IGTP TODAY

News

More efficient, reliable methods for Hepatitis C testing in vulnerable groups

In the latest installment of their work to reduce hepatitis C virus in Catalonia, and as part of the worldwide campaign to end viral hepatitis, Members of the Clinical Virology and New Diagnostic Tools Group at the IGTP have found that two diagnostic tests that can be carried out at the point of care are simple and effective methods for testing people who inject drugs, a group particlarly vulnerable to hepatitis C.

- Research

Spain currently has 124,300 active cases of COVID-19 according to the mathematical model developed by the UPC and IGTP

Madrid, Catalonia, Castile and León and Castile la Mancha are the autonomous regions with the highest accumulated numbers of active cases, in contrast, the Canary Islands, Cantabria, La Rioja, Murcia and Asturias have the lowest numbers of active cases. The data forms part of the study of the evolution of the pandemic based on mathematical models being carried out by the multi-disciplinary team of researchers of the UPC and IGTP.

- Research

The malaria parasite ‘P. vivax’ can remain in the spleen upon expression of certain proteins

The malaria parasite Plasmodium vivax can adhere to human spleen cells through the expression of so-called variant proteins. These are the conclusions of a study led by the Barcelona Institute for Global health (ISGlobal), an institution supported by "la Caixa" and the Germans Trias i Pujol Research Institute (IGTP). The results, published in PNAS, suggest that this could represent an additional challenge to eliminating the disease.

- Innovation, Research

The IGTP participates in an international project to validate serological tests for COVID-19

The Innovation in Respiratory Infection and Tuberculosis Diagnosis research group led by Dr José Dominguez and Dr Cristina Prat Aymerich have started a collaboration with the team led by Dr Lluis Cuevas at the Liverpool School of Tropical Medicine to develop and validate new serological techniques for diagnosing COVID-19. The project is financed by the Wellcome Trust (UK).

- Research

Artificial intelligence identifies a new drug for beta cell regeneration in type 1 diabetes

Researchers from IGTP have published an article on the identification of a drug for beta cell regeneration in type 1 diabetes. The drug is already licenced for use in people with type 2 diabetes. Using artificial intelligence researchers selected the drug from 6,605 candidates and tested it in mouse models. The drug improved hyperglycaemia and results indicate that beta cell replacement took place. More research is needed to explore its use as a new therapy for beta cell regeneration, which should be combined with an immunomodulatory strategy to reduce autoimmunity.

- Research

The IGTP contributes to the European Society of Endocrinology statement on COVID-19 and endocrine diseases

Manel Puig, acting director of the IGTP, has been one of a distinguished team of three leading endocrinologists to publish a statement and general guidelines on behalf of the European Society of Endocrinology. The document includes advice for endocrinologists and also for patients with diabetes mellitus and other endocrine or metabolic diseases during the COVID-19 pandemic. The statement includes guidelines for patients on how to avoid infection and what to do when it is suspected.